Exelixis
EXEL
#1665
Rank
S$17.00 B
Marketcap
S$68.61
Share price
-0.99%
Change (1 day)
43.77%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): S$4.01

According to Exelixis's latest financial reports the company's current EPS (TTM) is S$3.98. In 2025 the company made an earnings per share (EPS) of S$3.68.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$4.019.14%
2025S$3.68
2023S$0.8314.61%
2022S$0.73-22.97%
2021S$0.94100%
2020S$0.47-65.09%
2019S$1.35-53.91%
2018S$2.93333.96%
2017S$0.67-260.61%
2016S-$0.42-58.75%
2015S-$1.02-42.45%
2014S-$1.775.3%
2013S-$1.68

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
S$11.12 179.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$1.67-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$18.43 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
S$3.26-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$4.55 14.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$4.53 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
S$4.95 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
S-$30.29-860.38%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
S-$1.07-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA